Last reviewed · How we verify
Apacil (AMINOSALICYLATE SODIUM)
At a glance
| Generic name | AMINOSALICYLATE SODIUM |
|---|---|
| Sponsor | Consolidated Midland |
| Drug class | aminosalicylic acid |
| Target | Tyrosine-protein phosphatase non-receptor type 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Acute tuberculosis
- Pulmonary tuberculosis
Common side effects
Key clinical trials
- The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apacil CI brief — competitive landscape report
- Apacil updates RSS · CI watch RSS
- Consolidated Midland portfolio CI